3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Breast
1
Conditions
Breast Neoplasms
125
Neoplasm Metastasis
17
Ovarian Neoplasms
12
Endometrial Neoplasms
9
Neoplasms
8
Triple Negative Breast Neoplasms
7
Carcinoma, Non-Small-Cell Lung
6
Uterine Cervical Neoplasms
5
Prostatic Neoplasms
5
Hereditary Sensory and Autonomic Neuropathies
5
Colorectal Neoplasms
5
Advanced Breast Cancer
5
Squamous Cell Carcinoma of Head and Neck
4
Stomach Neoplasms
3
Recurrence
3
Neoplasms by Site
3
Head and Neck Neoplasms
3
Carcinoma, Lobular
3
Breast Diseases
3
Breast Cancer Metastatic
3
Uterine Neoplasms
2
Small Cell Lung Carcinoma
2
Multiple Endocrine Neoplasia Type 1
2
Melanoma
2
Locally Advanced (Inoperable) or Metastatic Breast Cancer
2
Fallopian Tube Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Advanced Solid Tumors
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Interventions
Alpelisib
2
exemestane
1
Vildagliptin
1
Tamoxifen
1
Standard of Care
1
Metformin
1
Letrozole
1
Fulvestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hyperglycemia
×
Fulvestrant
×
1 year
×
Clear all
NCT04300790
2025-07-29
METALLICA
MedSIR
Phase 2
Completed
69 enrolled